Resultats globals: 4 registres trobats en 0.02 segons.
Articles, 4 registres trobats
Articles 4 registres trobats  
1.
18 p, 504.6 KB Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis : Results from Greater Than 17,000 Patient-Years of Exposure / Armstrong, April (Keck School of Medicine of the University of Southern California. Department of Clinical Research) ; Paul, Carle (Paul Sabatier University. Dermatology Department, Toulouse University Hospital (CHU)) ; Puig, Luis (Institut d'Investigació Biomèdica Sant Pau) ; Boehncke, Wolf Henning (University of Geneva. Department of Pathology and Immunology) ; Freeman, Michael (The Skin Centre, Benowa, QLD Australia) ; Torii, Hideshi (Tokyo Yamate Medical Center. Division of Dermatology) ; Papp, Kim (K Papp Clinical Research and Probity Medical Research) ; Griffiths, Christopher E. M. (NIHR Manchester Biomedical Research Centre. Dermatology Centre, Salford Royal Hospital, University of Manchester) ; Blauvelt, Andrew (Oregon Medical Research Center) ; Reich, Kristian (Skinflammation® Center, Hamburg, Germany) ; Gooderham, Melinda (Centre for Dermatology and Probity Medical Research, Peterborough, ON Canada) ; Terui, Tadashi (Nihon University School of Medicine. Department of Dermatology) ; Renda, Lisa (Eli Lilly and Company) ; Agada, Noah (Eli Lilly and Company) ; Xu, Wen (Eli Lilly and Company) ; Gallo, Gaia (Eli Lilly and Company) ; Lebwohl, Mark G. (Icahn School of Medicine at Mount Sinai. Department of Dermatology) ; Universitat Autònoma de Barcelona
Long-term safety data are critical for evaluating therapies for psoriasis. Ixekizumab has demonstrated efficacy and is well tolerated for the treatment of moderate-to-severe plaque psoriasis. We examined the safety and tolerability of up to 5 years of ixekizumab therapy in patients with psoriasis. [...]
2019 - 10.1007/s13555-019-00340-3
Dermatology and Therapy, Vol. 10 (november 2019) , p. 133-150  
2.
9 p, 310.0 KB Long-term safety and tolerability of apremilast in patients with psoriasis : Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2) / Crowley, Jeffrey (Bakersfield Dermatology) ; Thaçi, Diamant (Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein) ; Joly, Pascal (Department of Dermatology, Hôpital Charles Nicolle, Université de Rouen) ; Peris, Ketty (Universitá Cattolica del Sacro Cuore, Roma) ; Papp,Kim A. (Probity Medical Research, Waterloo) ; Gonçalves, Joana (Celgene Corporation) ; Day, Robert M. (Celgene Corporation) ; Chen, Rongdean (Celgene Corporation) ; Shah, Kamal (Celgene Corporation) ; Ferrándiz, Carlos (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Cather, Jennifer C. (Modern Research Associates, Dallas) ; Universitat Autònoma de Barcelona
BACKGROUND: Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis. OBJECTIVE: Assess long-term safety of oral apremilast in psoriasis patients. [...]
2017 - 10.1016/j.jaad.2017.01.052
Journal of the American Academy of Dermatology, Vol. 77 Núm. 2 (2017) , p. 310  
3.
1 p, 320.3 KB Correction to : Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) / Blauvelt, Andrew (SW Locust St., Suite G, Portland, OR 97223 USA) ; Papp, Kim A. (Waterloo, Canada) ; Griffiths, Christopher E. M. (Manchester, UK) ; Puig, Luis (Institut d'Investigació Biomèdica Sant Pau) ; Weisman, Jamie (Medical Dermatology Specialists, Inc., Atlanta, GA USA) ; Dutronc, Yves (Indianapolis, IN USA) ; Kerr, Lisa Farmer (Indianapolis, IN USA) ; Ilo, Dapo (Indianapolis, IN USA) ; Mallbris, Lotus (Indianapolis, IN USA) ; Augustin, Matthias (Hamburg, Germany) ; Universitat Autònoma de Barcelona
2018 - 10.1007/s40257-018-0353-x
American Journal of Clinical Dermatology, Vol. 19 (march 2018) , p. 457  
4.
8 p, 420.3 KB Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders : A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) / Blauvelt, Andrew (SW Locust St., Suite G, Portland, USA) ; Papp, Kim A. (Waterloo, Canada) ; Griffiths, Christopher E. M. (Manchester, UK) ; Puig, Luis (Institut d'Investigació Biomèdica Sant Pau) ; Weisman, Jamie (Medical Dermatology Specialists, Inc., Atlanta, GA USA) ; Dutronc, Yves (Indianapolis, IN USA) ; Kerr, Lisa Farmer (Indianapolis, IN USA) ; Ilo, Dapo (Indianapolis, IN USA) ; Mallbris, Lotus (Indianapolis, IN USA) ; Augustin, Matthias (Hamburg, Germany) ; Universitat Autònoma de Barcelona
Patients with psoriasis who have an inadequate response to one biologic may benefit from switching to a new biologic, such as ixekizumab, a high affinity monoclonal antibody that selectively targets interleukin (IL)-17A. [...]
2017 - 10.1007/s40257-016-0246-9
American Journal of Clinical Dermatology, Vol. 18 (january 2017) , p. 273-280  

Vegeu també: autors amb noms similars
1 Papp, K.
1 Papp, K.V.
2 Papp, Kim A.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.